Citations 15
Preface: promoting research in PLS: current knowledge and future challenges
Mitsumoto, Hiroshi , Conference, all Delegates of the PLS, Ajroud‐Driss, Senda , Andres, Patricia L., Andrews, Jinsy , Babu, Suma , Barohn, Richard J., Benatar, Michael, Chew, Sheena , Conwit, Robin , Davis, Frank, Drory, Vivian E., Elman, Lauren , Fernandes, J. Americo, Ferrey, Dominic, Finegan, Eoin, Fink, John K. , Floeter, Mary Kay, Fournier, Christina , Genge, Angela , Govindarajan, Raghav , Haase, Georg, Hardiman, Orla , Harms, Matthew B. , Hayat, Ghazala , Heiman‐Patterson, Terry , Hill, Bryan Alan, Hübers, Annemarie , Huey, Edward D. , Jawdat, Omar, Kano, Osamu , Kau, Kristen, Kiernan, Matthew C. , Kisanuki, Yasushi, Kurent, Jerome E., Kwan, Justin , Lange, Dale J. , Ludolph, Albert C. , Mackenzie, Ian R. , Manfredi, Giovanni , Marren, David, Family, and, Morita, Mitsuya , Murphy, Jennifer , Nations, Sharon , Oskarsson, Björn , Pellerin, David , Ravits, John , Rezania, Kourosh , Scelsa, Stephen N. , Siddique, Nailah, Simmons, Zachary , Statland, Jeffrey , Blitterswijk, Marka van , Berg, Leonard van den , Walk, David , Warden, Deborah L., Wymer, James , van Blitterswijk, Marka , Simmons, Zachary , Oskarsson, Björn , Hardiman, Orla , Kiernan, Matthew C , Walk, David , Turner, Martin R. , Conference, all Delegates of the PLS, Área-Gómez, Estela , Solano, Juan Marcos , Bede, Peter , Corcia, Philippe , Cudkowicz, Merit , Carvalho, Mamede A. de , Factor‐Litvak, Pam , Granit, Volkan , Family, and, Paganoni, Sabrina , Rouleau, Guy Armand , Siddique, Teepu , Silani, Vincenzo , Traynor, Bryan J.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | February 20, 2021 | Volume: 21 | Issue: sup1 | Pages: 1-2
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
Wainger, Brian J. , McIlduff, Courtney, Maragakis, Nicholas J. , Bedlack, Richard , Goyal, Namita , Rutkove, Seward B. , Lange, Dale J. , Rivner, Michael H. , Goutman, Stephen A. , Mauricio, Elizabeth A. , Baloh, Robert H. , Simmons, Zachary , Pothier, Lindsay , Kassis, Sylvia Baedorf , La, Thuong, Hall, Meghan, Evora, Armineuza, Klements, David , Hurtado, Aura, Pereira, João D. , Koh, Joan, Celnik, Pablo , Chaudhry, Vinay , Gable, Karissa , Juel, Vern C. , Phielipp, Nicolás , Marei, Adel, Rosenquist, Peter B. , Oskarsson, Björn , Lewis, Richard A. , Kaur, Divpreet, Kiskinis, Evangelos , Eggan, Kevin , Weiss, Michael D. , David, William S., Davila-Pérez, Paula , Camprodon, Joan A. , Kiernan, Matthew C. , Atassi, Nazem , Cudkowicz, Merit , Goutman, Stephen A , Simmons, Zachary , Oskarsson, Björn , Maragakis, Nicholas , Bedlack, Richard S , Cudkowicz, Merit E , Kiernan, Matthew C , Macklin, Eric A. , Vucic, Steve , Paganoni, Sabrina , Ladha, Shafeeq , Mauricio, Elizabeth A. , Puerto, Aura Maria Hurtado , Meehan, Sean K. , Woolf, Clifford J. , Berry, James D. , Pascual‐Leone, Álvaro , Shefner, Jeremy M.
JAMA Neurology | November 23, 2020 | Volume: 78 | Issue: 2 | Pages: 186
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
Andrews, Jinsy , Genge, Angela , Jackson, Carlayne E. , Miller, Timothy M. , Cockroft, Bettina M., Meng, Lisa , Wei, Jenny , Wolff, Andrew A. , Malik, Fady I. , Bodkin, Cynthia, Dionne, Annie , Fee, Dominic B. , Goutman, Stephen A. , Goyal, Namita , Hardiman, Orla , Hayat, Ghazala , Heiman‐Patterson, Terry , Heitzman, Daragh, Johnston, Wendy , Kiernan, Matthew C. , Korngut, Lawrence , Matte, Geneviève, Mora, Jesús S., Needham, Merrilee , Oskarsson, Björn , Pattee, Gary L. , Pulley, Michael , Quan, Dianna , Rezania, Kourosh , Schellenberg, Kerri , Schultz, David , Shoesmith, Christen , Simmons, Zachary , Statland, Jeffrey , Sultan, Shumaila, Weiss, Michael D. , Whyte-Rayson, Ashley, Wymer, James , Zinman, Lorne , Rudnicki, Stacy A. , Oskarsson, Björn , Schellenberg, Kerri L , Goutman, Stephen A , Simmons, Zachary , Hardiman, Orla , Kiernan, Matthew C , Shefner, Jeremy M. , Lechtzin, Noah , Brooks, Benjamin Rix , Caress, James B. , Henderson, Robert D. , Karam, Chafic , Kolb, Stephen J. , Ladha, Shafeeq , Pioro, Erik P. , Swenson, Andrea , Berg, Leonard H. van den , Vu, Tuan , Vucic, Steve
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | September 24, 2020 | Volume: 22 | Issue: 3-4 | Pages: 287-299
Primary lateral sclerosis (PLS) functional rating scale: PLS‐specific clinimetric scale
Mitsumoto, Hiroshi , Chiuzan, Codruța , Gilmore, Madison , Zhang, Yuan , Simmons, Zachary , Kisanuki, Yasushi, Zinman, Lorne , Jawdat, Omar, Sorenson, Eric J. , Floeter, Mary Kay, Filho, J. Americo M. Fernandes, Heitzman, Daragh, Fournier, Christina , Oskarsson, Björn , Heiman‐Patterson, Terry , Maragakis, Nicholas J. , Joyce, Nanette C. , Hayat, Ghazala , Nations, Sharon , Scelsa, Stephen N. , Walk, David , Elman, Lauren , Hupf, Jonathan , McHale, Brittany , group, the PLSFRS study, Sorenson, Eric, Simmons, Zachary , Oskarsson, Björn , Maragakis, Nicholas , Walk, David , Paganoni, Sabrina , Pioro, Erik P. , group, the PLSFRS study
Muscle & Nerve | November 23, 2019 | Volume: 61 | Issue: 2 | Pages: 163-172
AbstractIntroductionOur research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS).MethodsA prototype of the PLS Functional Rating Scale (PLSFRS) was generated. Seventy‐seven participants with PLS were enrolled and evaluated at 21 sites that comprised the PLSFRS study group. Participants were assessed using the PLSFRS, Neuro‐Quality of Life (QoL), Schwab‐England Activities of Daily Living (ADL), and the Clinical Global Impression of Change scales. Participants completed telephone assessments at 12, 24, and 48 weeks after enrollment.ResultsThe PLSFRS demonstrated internal consistency as well as intrarater, interrater, telephone test‐retest reliability, and construct validity. Significant changes in disease progression were detected at 6 and 12 months; changes measured by the PLSFRS vs the ALSFRS‐R were significantly higher.DiscussionThe PLSFRS is a valid tool to assess the natural history of PLS in a shorter study period.
Amyotrophic lateral sclerosis–specific quality of life–short form (ALSSQOL‐SF): A brief, reliable, and valid version of the ALSSQOL‐R
Felgoise, Stephanie H. , Feinberg, Richard A. , Stephens, Helen , Clawson, Lora , Elman, Lauren , Goutman, Stephen A. , McCluskey, Leo, Russell, James W. , Tiryaki, Ezgi , Weiss, Michael D. , Simmons, Zachary , Boylan, Kevin, Goutman, Stephen A , Simmons, Zachary , Barkhaus, Paul E. , Boylan, Khrista , Caress, James B.
Muscle & Nerve | July 20, 2018 | Volume: 58 | Issue: 5 | Pages: 646-654
ABSTRACT Introduction: The Amyotrophic Lateral Sclerosis (ALS)‐Specific Quality of Life instrument and its revised version (ALSSQOL and ALSSQOL‐R) have strong psychometric properties, and have demonstrated research and clinical utility. In this study we aimed to develop a short form (ALSSQOL‐SF) suitable for limited clinic time and patient stamina. Methods: The ALSSQOL‐SF was created using Item Response Theory and confirmatory factor analysis on 389 patients. A cross‐validation sample of 162 patients assessed convergent, divergent, and construct validity of the ALSSQOL‐SF compared with psychosocial and physical functioning measures. Results: The ALSSQOL‐SF consisted of 20 items. Compared with the ALSSQOL‐R, optimal precision was retained, and completion time was reduced from 15–25 minutes to 2–4 minutes. Psychometric properties for the ALSSQOL‐SF and its subscales were strong. Discussion: The ALSSQOL‐SF is a disease‐specific global QOL instrument that has a short administration time suitable for clinical use, and can provide clinically useful, valid information about persons with ALS. Muscle Nerve 58: 646–654, 2018